Matt Abernethy - 13 Aug 2024 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Financial Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
13 Aug 2024
Net transactions value
-$1,082,587
Form type
4
Filing time
15 Aug 2024, 17:12:01 UTC
Previous filing
18 Jul 2024
Next filing
04 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $1,037,760 +14,100 +45% $73.60 45,628 13 Aug 2024 Direct
transaction NBIX Common Stock Sale $2,120,347 -14,100 -31% $150.38 31,528 13 Aug 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Non-Qualified Stock Option Options Exercise $0 -14,100 -100% $0.000000* 0 13 Aug 2024 Common Stock 14,100 $73.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $151.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Option granted December 1, 2017 and vested at 25% upon the first anniversary (December 1, 2018) and the remaining 75% vested in 36 equal monthly installments beginning January 1, 2019.